Frequency Therapeutics announced topline results from its recent study, showing that four weekly injections of its FX-322 treatment therapy in subjects with mild to moderately severe sensorineural hearing loss (SNHL) did not demonstrate improvements in hearing measures versus placebo. FX-322, the company’s lead product candidate, made news last month when a study published in ‘Otology & Neurotology’ indicated the “first known linkage of pharmacokinetics and pharmacodynamics for a potential hearing restoration therapy.”